Press release
Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
Collaboration to combine Moderna's mRNA platform with Life Edit's proprietary gene editing technologies, including base editing capabilitiesMulti-target
About this update from Moderna, Inc.
[{"type":"text","content":"Collaboration to combine Moderna's mRNA platform with Life Edit's proprietary gene editing technologies, including base editing capabilitiesMulti-target collaboration to advance potentially life-transformative or curative therapies for some of the most challenging genetic diseasesLife Edit to receive upfront cash payment, research, and preclinical funding, and is eligible to receive milestone payments with tiered royalties on global net product salesCAMBRIDGE, MA and DURHAM, NC / ACCESSWIRE / February 22, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines and Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit's suite of proprietary gene editing technologies, including base editing, with Moderna's mRNA platform to advance in vivo gene editing therapies against a select set of therapeutic targets. mRNA may hold promise in the delivery of gene-editing technology, which has the potential to treat or cure rare genetic and other diseases.\"This collaboration between Life Edit and Moderna demonstrates the strength of our respective technologies to advance programmable medicines to more specifically target disease,\" said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio. \"Our novel editing systems have the potential to precisely modify gene targets for both in vivo and ex vivo therapeutic development. We are excited that partners, such as Moderna, are recognizing the potential of our technology.\"Life Edit's gene editing platform offers a large and diverse library of base editors and RNA-guided nucleases (RGNs). The RGNs are smaller in size when compared to conventional nucleases, potentially enabling greater versatility for delivery. Life Edit's nuclease collection features a range of Protospacer Adjacent Motifs (PAMs), short sequences that determine the DNA segments in the genome to which a nuclease can bind. The diversity of Life Edit's PAM collection enables base editing at more sites than any one nuclease could achieve, offering unprecedented access to the genome to target diseas...